class of drugs
POPULARITY
Join us as we talk with Prof Prash Sanders about the role of anticoagulation for patients with atrial fibrillation (AF), learn when patients should be screened for AF, how to perform a stroke risk assessment and strategies to reduce the risk of bleeding. This podcast is in collaboration with Medcast and the Quality Use of Medicines Alliance, a provider of health professional education in Australia focused on the quality use of medicines. Check out their resources here. Clinical guide: Anticoagulant management for AF Anticoagulant patient care plan Prof Prash Sanders is a cardiologist and electrophysiologist with a focus on heart rhythm disorders, particularly atrial fibrillation. He graduated with Honours from the University of Adelaide and completed advanced training in Melbourne and Bordeaux, France, earning national and international recognition for his research and clinical expertise. He is the Clinical Director of Cardiac Electrophysiology at the Royal Adelaide Hospital and holds the Knapman – National Heart Foundation Chair of Cardiology Research at the University of Adelaide. Dr Sanders has published over 600 papers and is a leader in advanced ablation techniques. He consults and performs procedures across multiple hospitals and regional clinics in South Australia. Jarrah is a clinical pharmacist with a passion for education and quality use of data. He has led national health programs, including GP audit and feedback initiatives and Indigenous health nKPIs. He is currently clinical lead at MedCast, supporting best practice care through the Quality Use of Medicines Alliance.
This episode covers: Cardiology This Week: A concise summary of recent studies Oral anticoagulation in atrial fibrillation: answers to frequent questions Smartwatch, heart rate and ECG Milestones: Lyon Diet Heart study Host: Emer Joyce Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Anticoagulation with AF and Cancer Guest: Nicholas Tan, M.D., M.S. Host: Anthony H. Kashou, M.D. In today's episode of ECG Making Waves, Dr. Anthony Kashou interviews Dr. Nicholas Tan on how to manage anticoagulation in patients with cancer. They discuss the importance of appreciating the challenging balance in managing stroke risk in patients with cancer and atrial fibrillation. After listening to this episode, listeners will understand alternative strategies for stroke prevention in addition to systemic anticoagulation. Topics Discussed: What is the relationship between cancer and atrial fibrillation? Why is stroke prevention challenging in this situation? What is the role of left atrial appendage closure in cancer patients? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.
Dr. Dan Ackerman and Dr. James Ernest Siegler discuss the complexities of treating ESUS and emphasize the importance of personalized treatment approaches based on individual patient factors. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213876
Dr. Dan Ackerman talks with Dr. James Ernest Siegler about the complexities of treating ESUS and emphasizes the importance of personalized treatment approaches based on individual patient factors. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
Master the latest approaches for treating venous thromboembolism with expert tips on direct oral anticoagulant (DOAC) selection, dosing, and duration. Learn how to tailor anticoagulation for special populations, handle treatment failures, and navigate long-distance travel risks. We're joined by Dr. Tara Lech, PharmD, CACP (Beth Israel Lahey Health, @AnticoagPharmD, @anticoagpharmd.bsky.social). Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case 1 from Kashlak Choosing the right anticoagulant Distal deep vein thrombosis management Anticoagulation in special populations Case 2 from Kashlak Understanding treatment failure Anticoagulation reversal agents Outro Credits Producer, Writer, Show Notes, Infographic, Cover Art: Ben Furman Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP Reviewer: Leah Witt, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Tara Lech, PharmD Disclosures Dr. Lech reports no relevant financial disclosures. The Curbsiders report no relevant financial disclosures. Sponsor: Grammarly Let Grammarly take the busywork off your plate so you can focus on high-impact work. Download Grammarly for free at Grammarly.com/PODCAST. Sponsor: Freed CURB50 to get $50 off your first month when you subscribe at freed.ai Sponsor: JournalFeed Try JournalFeed free for 7 days—and get 20% off your first year with code CURB25 at journalfeed.org/curb.
Oral antiarrhythmics have limited efficacy and significant risks Catheter ablation is now a first-line option in suitable patients Newer ablation technology - Pulsed field ablation (PFA) is safer and faster Anticoagulation decisions remain based on stroke risk, not ablation status Genuine post-procedural issues may be benign Ongoing healthcare professional role - Blood pressure and risk factor control The questions answered in this podcast are listed below.They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars. How effective are oral antiarrhythmic medications? Does this cure atrial fibrillation? What is the current state of ablation technology? Can you explain what you mean by "rapid" and provide an example of how long a procedure typically takes? Does reduced scarring decrease the likelihood or complexity of needing a repeat ablation? What are some of the contraindications in terms of structurally abnormal heart that would be contraindications for the patient? How should atrial fibrillation be approached in patients with severe ischaemic heart disease? Does this complicate treatment? If a patient has an AF ablation, can they come off my anticoagulant? How do you manage patient’s embolic issues? How soon after the procedure can patients typically be discharged? Following successful AF suppression, is it possible for patients to stop taking DOACs or other anticoagulants? After discharge, how soon should patients follow up with their GP? What should the GP monitor and what should be communicated back to the specialist? When will you consider AV node ablation and insertion of a pacemaker? Host: David Lim | Total Time: 44 mins Expert: Prof Rukshen Weerasooriya, Sub-specialist Cardiac Electrophysiologist Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.
Send us a Text Message (please include your email so we can respond!)Episode 66! Today we talk about Acute Chest Syndrome in Sickle Cell Disease with one of our favorite hematologists, Benjamin Tillman! We base our discussion around the TASC trial or "Comparison of Prophylactic and Therapeutic Doses of Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease" published by Dessap et al in AJRCCM April of 2025.Pubmed: https://pubmed.ncbi.nlm.nih.gov/40209087/AJRCCM: https://www.atsjournals.org/doi/10.1164/rccm.202409-1727OCIf you enjoy the show be sure to like and subscribe, leave that 5 star review! Be sure to follow us on the social @icucast for the associated figures, comments, and other content not available in the audio format! Email us at icuedandtoddcast@gmail.com with any questions or suggestions! Thank you Mike Gannon for the intro and exit music!
In this episode of Medicine Grand Rounders, we're join by hematologist extrodinaire Dr. Dana Angelini, who goes over the do's and don'ts of anticoagulation for the Internal Medicine Physician. Moderated by: Seysha Mehta, MS3
The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I The KETO-CTA Study JACC Advances Paper: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101686 Meta-analysis https://doi.org/10.1016/j.ajcnut.2024.01.009 II Subclinical AF – Anticoagulate or Not? Anticoagulation in Subclinical AF May Offer Little Benefit https://www.medscape.com/viewarticle/anticoagulation-subclinical-af-may-offer-little-benefit-2025a1000b31 Treat AFib ‘Diagnosed' by Smartwatch https://www.medscape.com/viewarticle/treat-afib-diagnosed-smartwatch-2025a1000avp JAMA NO paper https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833437 NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062 ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234 McIntyre meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512 Singer et al https://pmc.ncbi.nlm.nih.gov/articles/PMC2777526/ Stroke paper https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.123.045843 American Journal of Medicine paper https://pubmed.ncbi.nlm.nih.gov/38331136/ III GLP1a for Treatment of Fatty Liver Disease ESSENCE trial https://www.nejm.org/doi/10.1056/NEJMoa2413258 Features CABG Still Superior to Stents Despite FAME 3 Endpoint Swap https://www.medscape.com/viewarticle/cabg-still-superior-stents-despite-fame-3-endpoint-swap-2025a1000ao5 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net
This week, we discuss another set of high yield topic for anyone who cares for patients on anticoagulation - how to safely hold anticoagulation prior to a procedure and how to reverse the effects of the drug in the even of an emergent situation. We discuss our approach to how we discuss this with our patients and our medical colleagues! Dan also shares his dotphrases for your reference! Episode contents:- How do we approach peri-operative anticoagulation management? When do we hold? How long do we hold? Do they need bridging? No bridging? - In the case of a severe bleed, how do we reverse the effects of anticoagulation?**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast
Dr. Ziv Harel discusses findings from his study, "Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis: A Pilot Randomized Controlled Trial," with JASN Deputy Editor Manjula Kurella Tamura.
Interview with Steven J. Warach, MD, PhD, author of Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
Interview with Steven J. Warach, MD, PhD, author of Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
For this episode we are joined by EBM guru, Dr. Brian Locke, who deftly breaks down all of our statistics questions. Is half dose DOAC as good as full dose DOAC for preventing VTE, and does it reduce bleeding risk? Can procalcitonin reduce duration of antibiotics for infections without compromising mortality rates? Can LLMs like GPT-4 help physicians manage patients better? Can reinforcement learning models predict when to start vasopressin in patients with septic shock? What is the risk of resuming anticoagulation in patients with atrial fibrillation and prior intracerebral hemorrhage? Is high flow nasal cannula as good as non-invasive ventilation for different types of respiratory failure? We answer all these questions and more!Half Dose DOAC for Long Term VTE Prevention (RENOVE)Biomarker-Guided Antibiotic Duration (ADAPT-Sepsis)GPT-4 Assistance for Physician PerformanceOptimal Vasopressin Initiation for Septic Shock (OVISS)DOACs for A fib after ICH (PRESTIGE-AF)High Flow Nasal Cannula vs NIV for Respiratory Failure (RENOVATE)Music from Uppbeat (free for Creators!): https://uppbeat.io/t/soundroll/dope License code: NP8HLP5WKGKXFW2R
Blood clots can be life-threatening, but understanding their causes and treatments can save lives. In Part 2 of our Hematology Series, Dr. Andrew Jenzer, DDS, dives deep into thrombosis, breaking down the three key contributing factors and the most common hypercoagulable conditions. We carefully dissect the pathophysiology of pulmonary embolisms, the most important guidelines to know and follow, the difference between provoked and unprovoked hypercoagulable conditions, and everything you need to know about the perioperative management of antithrombotic therapies. To close, Dr. Jenzer highlights the critical risk factors of preoperative anticoagulation and key takeaways from our conversation that should never be forgotten. If you're a healthcare professional or simply someone who values life-saving knowledge, this episode is packed with insights you won't want to miss. Tune in to sharpen your expertise and improve patient outcomes!Key Points From This Episode:Three contributors to thrombosis and the most common hypercoagulable conditions.Unpacking the pathophysiology of pulmonary embolisms.Wells' Criteria, CHEST, and other crucial guidelines to follow. The difference between provoked and unprovoked hypercoagulable conditions. Anticoagulation therapies and important surgical considerations.Risk factors associated with the perioperative management of antithrombotic therapy. Recapping the key takeaways from today's conversation. Links Mentioned in Today's Episode:Dr. Andrew Jenzer Email — andrew.jenzer@gmail.com Dr. Andrew Jenzer | Duke Surgery — https://surgery.duke.edu/profile/andrew-clark-jenzer ACOMS | Annual Winter Meeting — https://www.acoms.org/Events/Winter-Meeting/About Wells' Criteria for Pulmonary Embolism — https://www.mdcalc.com/calc/115/wells-criteria-pulmonary-embolism Wells' Criteria for DVT — https://www.mdcalc.com/calc/362/wells-criteria-dvt American College of Chest Physicians — https://www.chestnet.org/ ‘Perioperative Management of Antithrombotic Therapy' — https://www.chestnet.org/guidelines-and-topic-collections/guidelines/pulmonary-vascular/perioperative-management-of-antithrombotic-therapy ‘Perioperative Management of Patients with Atrial Fibrillation Receiving a Direct Oral Anticoagulant' — https://pubmed.ncbi.nlm.nih.gov/31380891/ ‘Perioperative Optimization and Management of the Oral and Maxillofacial Surgical Patient' — https://pubmed.ncbi.nlm.nih.gov/38103577/ Everyday Oral Surgery Website — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/ Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/Dr. Grant Stucki Email — grantstucki@gmail.comDr. Grant Stucki Phone — 720-441-6059
In this episode, Dr. Valentin Fuster summarizes the March 25, 2025, issue of the JACC, which focuses on advancements in electrophysiology. Highlights include groundbreaking studies on leadless pacemakers, atrial fibrillation treatments, and appropriate use criteria for cardiac devices, with key papers exploring the safety of pacemaker retrieval, the role of electrograms in ablation procedures, and long-term outcomes for left atrial appendage occlusion devices.
HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast
In this episode, we review the new 2025 ACC/AHA Acute Coronary Syndrome (ACS) guidelines, with a particular focus on guideline recommendations for analgesics, P2Y12 inhibitors, parenteral anticoagulation, and lipid management. Key Concepts Nitrates and opioids are recommended for symptomatic relief of chest pain. Some patients may not be appropriate for nitrates (e.g. recent PDE-5 inhibitor use, hypotension, or right ventricular infarction). Opioids are used for nitrate-refractory angina but have a theoretical risk of delaying the effect of oral antiplatelet medications. Prasugrel and ticagrelor are preferred P2Y12 inhibitors over clopidogrel in most patients. Patient-specific factors, including the use of PCI, play a role in P2Y12 inhibitor selection. Anticoagulation with heparin is recommended in nearly all acute coronary syndrome (ACS) scenarios. Alternative anticoagulants may be used depending on whether PCI/CABG is planned and whether the anticoagulant is used prior to PCI/CABG (“upstream”) or during the PCI procedure itself. LDL goals after ACS have changed again. All ACS patients should have an LDL goal < 70 with a consideration of an LDL goal of 55-69. A variety of non-statin therapies may be added to a high intensity statin regimen if LDL is not at goal. References Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online February 27, 2025. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001309
In this episode, Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss: Workup of COVID-19 in the emergency departmentMethods of COVID-19 risk stratification Treatment recommendations for people with severe COVID-19, including how to effectively use antiviral therapy, dexamethasone, and other immunomodulators[CC1] in this population A detailed patient case to illustrate key takeawaysPresenters:Stephen Cantrill, MD, FACEPAssociate Director and Medical Director (Retired) Department of Emergency Medicine Denver Health Medical Center Associate Professor Department of Emergency Medicine University of Colorado Health Sciences Center Denver, Colorado Rajesh T. Gandhi, MDMassachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Payal K. Patel, MD, MPH, FIDSASystemwide Director of Antimicrobial Stewardship Associate Professor, Division of Infectious Diseases Intermountain Health Salt Lake City, Utah Link to full program: https://bit.ly/4gu2gcUGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss treatment strategies for people who have severe COVID-19, including: Antiviral therapy with remdesivir Dexamethasone and other systemic corticosteroids Immunomodulators, such as JAK inhibitors or IL-6 inhibitors Overviews of clinical trial data demonstrating how and when to use these therapiesPresenters:Stephen Cantrill, MD, FACEPAssociate Director and Medical Director (Retired) Department of Emergency Medicine Denver Health Medical Center Associate Professor Department of Emergency Medicine University of Colorado Health Sciences Center Denver, Colorado Rajesh T. Gandhi, MDMassachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Payal K. Patel, MD, MPH, FIDSASystemwide Director of Antimicrobial Stewardship Associate Professor, Division of Infectious Diseases Intermountain Health Salt Lake City, Utah Link to full program: https://bit.ly/4gu2gcUGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-translate-real-world-vte-data-into-everyday-clinical-practice-for-ongoing-anticoagulation/32303/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.
The POPular PAUSE TAVI trial investigated whether continuing or interrupting oral anticoagulation during transcatheter aortic valve implantation (TAVI) affected clinical outcomes. The randomized, open-label, noninferiority study included 858 patients and assessed a composite primary outcome of cardiovascular death, stroke, myocardial infarction, major vascular complications, or major bleeding at 30 days. The trial found that continuation was not noninferior to interruption, with higher bleeding risk but no significant difference in thromboembolic events, supporting interruption of anticoagulation in high-bleeding-risk TAVI patients.
We're back, after a brief hiatus! Today we talk about duration of therapy for bacteremia, Factor XI inhibition for atrial fibrillation, whether to stop ACEi or ARB before elective surgery, and whether GLP-1 agonists are beneficial in heart failure with preserved ejection fraction. Go to minute 7:30 to skip the banter. 7 vs 14 Days of Antibiotics for Bacteremia (BALANCE)Abelacimab vs Rivaroxaban for Atrial Fibrillation (AZALEA-TIMI-71)Asenduxian vs Apixaban for Atrial Fibrillation (OCEANIC-AF)ACEi or ARB Discontinuation Before Surgery (STOP or NOT)Tirzepatide for HFpEF and Obesity (SUMMIT)Music from Uppbeat (free for Creators!):https://uppbeat.io/t/soundroll/dopeLicense code: NP8HLP5WKGKXFW2R
OPTION - Randomized Comparison of Left Atrial Appendage Closure with Oral Anticoagulation after Catheter Ablation for Atrial Fibrillation (OPTION)
Anticoagulation in Rural EM - Part One by SAEM
Anticoagulation in Rural EM - Part Two by SAEM
Anticoagulation in Rural EM - Part One by SAEM
Anticoagulation in Rural EM - Part Two by SAEM
Anticoagulation in Rural EM by SAEM
Dr Tony Wan shares the results of a study that examined the effectiveness of an anticoagulation stewardship program (ACSP) in improving adherence to venous thromboembolism (VTE) prophylaxis guidelines and reducing costs at a Canadian teaching hospital. Here what he has to say about the results and the process of setting up the study in his hospital.Tony Wan, Stephanie J. Garland, Chipman Taylor Drury, Justin Lambert, Joshua Yoon, Melissa Chan, Anticoagulation stewardship: Improving adherence to clinical guidelines and reducing overuse of venous thromboembolism prophylaxis in hospitalized medical patients, Thrombosis Research, Volume 239, 2024, https://www.sciencedirect.com/science/article/pii/S0049384824001622 Donate to Thrombosis Canada: https://thrombosiscanada.ca/donateSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
POPular PAUSE TAVI – Continuation or Interruption of Oral Anticoagulation During TAVI?
Micaela Warfield, PharmD shares updates on the timing of anticoagulation following stroke secondary to atrial fibrillation. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE
Dr. Jodie Roberts and Dr. Amra Sakusic discusses the relationship between reversal therapy and ischemic stroke, between duration off anticoagulation and risk of ischemic strokes or systemic embolism. Learn more about the Neurology Practice Current section and fill out the survey now. Show reference: https://survey.alchemer.com/s3/7969148/Practice-Current-When-do-you-start-anticoagulation-therapy-for-patients-with-both-ICH-and-AF https://www.neurology.org/doi/10.1212/WNL.0000000000209664
In this episode, Dr. Valentin Fuster discusses a pivotal study comparing bivalirudin and heparin anticoagulation in STEMI patients undergoing primary PCI, highlighting that bivalirudin may reduce cardiac mortality and bleeding without increasing thrombotic events. While the findings challenge previous guidelines favoring heparin, limitations in the research prompt caution about immediate changes to clinical practice, emphasizing the need for further exploration of bivalirudin's role in diverse patient populations.
Host Samantha Gambles Farr, MSN, AG-ACNP, FNP-C, RNFA, is joined by Roman Melamed, MD, to discuss the comparative effectiveness of reduced-dose versus full-dose alteplase for acute pulmonary embolism, focusing on patient outcomes and complications. They will highlight study findings on significant improvements in hemodynamic and respiratory parameters in both groups, with a lower rate of hemorrhagic complications in the reduced-dose group (Melamed R, et al. Crit Care Med. 2024;52:729-742). Dr. Melamed is a critical care intensivist and director of the Pulmonary Embolism Program at Abbott Northwestern Hospital in Minneapolis, Minnesota, USA, and an adjunct associate professor at the University of Minnesota.
It's been a long time, but we are back!Apologies on the audio quality from Dr. Jenkins. Apparently he was recording from inside a cardboard box.Today we talk about important, practice changing studies in internal medicine from the last several months. What's the best anticoagulant in patients with cirrhosis and atrial fibrillation? Why do doctors use so much unfractionated heparin for acute PE? Should we still be using beta blockers in patients with acute MI? Does finerenone improve outcomes in HFpEF? Is continuous infusion of antibiotics better than intermittent? And will the cefepime vs piperacillin-tazobactam battle ever end?Apixaban, Rivaroxaban and Warfarin in Cirrhosis for AFAnticoagulation Trends for Acute PEBeta Blockers for Acute MI with Normal EF Finerenone for HFpEF FINEARTS-HFContinuous vs Intermittent Infusion of Beta-Lactams BLING IIIProlonged vs Intermittent Infusions of Beta-Lactams Meta-analysisPiperacillin-Tazobactam vs Cefepime for SepsisRecurrent SBP in Patients on Secondary Prophylaxis
Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.
Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.
Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.
In this episode, we talk with Dr. Frank Peacock and Dr. Jame Neuenschwander about the current statue of VTE, DVT, PE, and AFib management, as well as the approach to anticoagulation reversal. Great podcast on a common EM presentation and opportunities in EM. ACEP POC Tools - https://poctools.acep.org/
Dr. Dan Ackerman and Dr. Luciano A. Sposato discuss the topic of embolic stroke of undetermined sources and the controversies surrounding cardiac monitoring and anticoagulation. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209535
Dr. Dan Ackerman talks with Dr. Luciano A. Sposato about the topic of embolic stroke of undetermined source and the controversies surrounding cardiac monitoring and anticoagulation. Read the related article in Neurology. Disclosures can be found at Neurology.org.
** Be sure to check out our rotation guide for more show notes and episodes organized by disease type: https://www.thefellowoncall.com/rotation-guides** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast
An exciting new academic year is about to begin. We know this can be daunting, especially for our newest hematology/oncology fellows. Over the next two weeks, we re-boot some of our high yield episodes you need to know to prepare for your first days as a new fellow and your nights on call. Next up: When anticoagulation fails, Part 1! [Originally episode 079]Content: - How to approach a "DOAC failure" situation - When to consider warfarin** Be sure to check out our rotation guide for more show notes and episodes organized by disease type: https://www.thefellowoncall.com/rotation-guides** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast
Join us as we review recent articles and news featured in The DIGEST #48, #49, and #50 including thromboprophylaxis for patients receiving chemotherapy, eosinophil count to guide steroids in COPD exacerbations, anticoagulation in subclinical atrial fibrillation, the new genetic testing recommendations for patients with breast cancer, and at-home STI testing–not to mention trial names galore. Fill your brain hole with a fully digestible meal! Featuring Paul Williams (@PaulNWilliamz), Nora Taranto (@norataranto) and Matt Watto (@doctorwatto). Claim CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | CME! Credits Written and Hosted by: Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Cover Art: Nora Taranto MD Reviewer: Emi Okamoto MD Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments 00:00 Introduction + Pun 06:06 Target TP Trial: Thromboprophylaxis in Cancer Patients 13:07 Steroids for COPD Exacerbations 25:25 Anticoagulation in Subclinical Atrial Fibrillation 34:01 Genetic Testing in Breast Cancer 43:38 Home STI Testing Transcript Disclaimer We've included a a free AI-generated transcript which has not been corrected by a human for accuracy or completeness. Please consider this a starting point for further research and consultation. We disclaim any liability for damages or losses resulting from this content. Sponsor: Factor Head to FactorMeals.com/curb50 and use code curb50 to get 50% off. Sponsor: NetSuite Download NetSuite's popular KPI Checklist, designed to give you consistently excellent performance - absolutely free, at NetSuite.com/CURBSIDERS. Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month.